



News Release
For Immediate Distribution

CQDM receives funding of \$ 11.7 M from the Federal Government

Montreal – February 13 2013 – CQDM is pleased to announce the renewal of its funding from the Business-led Networks of Centres of Excellence (BL-NCE) for a total amount of \$ 11.7 M.

"This news is a proof of the pertinence and effectiveness of CQDM. From its inception, our organization has focused on cooperative research, a different approach to fund innovation. This view is now shared by more and more companies and proves that we were right to propose new avenues in drug research", says Diane Gosselin, CEO.

Since its inception, CQDM has funded 25 research projects for a total of 29.4 M dollars through 32 research units, including 19 public establishments and 13 private companies (SMEs). Over the past four years, CQDM has created an ecosystem where over 360 researchers from the pharmaceutical industry, Life Sciences sector and academia work in close collaboration.

"One of the unique strengths of the BL-NCE program is that it provides a way for multiple companies in the same sector to work together on a shared R&D agenda", said Suzanne Fortier, Chair of the NCE Steering Committee and President of the Natural Sciences and Engineering Research Council. "It also allows the private sector to set the research agenda by identifying the most appropriate challenge for the network to address".

"This funding will allow us not only to pursue our mission, but also to strengthen our image and leadership in Quebec, Canada and internationally", says Leon Gosselin, Chairman of CQDM's Board of Directors who welcomes this excellent news.

About CQDM

CQDM is a meeting ground for all stakeholders in biopharmaceutical research. Its principal mission is to fund research projects carried out in partnership between the academic and private sectors. An innovative Canadian initiative, CQDM has two major goals: to accelerate the drug discovery process and to develop safer and more effective drugs. CQDM is funded through contributions from Pfizer Canada, AstraZeneca, Merck, Boehringer Ingelheim (Canada) Ltd., GlaxoSmithKline Inc., Eli Lilly Canada Inc., Novartis Pharmaceuticals Canada Inc., the Business-Led Networks of Centres of Excellence (BL-NCE) and the Ministère de l'Enseignement supérieur, de la Recherche, de la Science et de la Technologie du Québec. For more information: www.cqdm.org.

For more information please contact:

Diane Gosselin, Ph.D., MBA
President and CEO
CQDM
514-594-7286
dgosselin@cqdm.org